Nu Skin Enterprises Inc. (NUS) Misses Q2 EPS by 14c; Warns for Q3

Nu Skin Enterprises Inc. (NYSE: NUS) reported Q2 EPS of $1.13, $0.14 worse than the analyst estimate of $1.27. Revenue for the quarter came in at $650 million versus the consensus estimate of $709.03 million.

Nu Skin Enterprises Inc. sees Q3 2014 EPS of $0.90-$0.95, versus the consensus of $1.68. Nu Skin Enterprises Inc. sees Q3 2014 revenue of $620-640 million, versus the consensus of $847.5 million.

"Our business performed in-line with our guidance for the quarter, with the exception of the China LTO, which occurred shortly after resuming our promotional efforts and did not meet our expectations," said Truman Hunt, president and chief executive officer. "We are pleased, however, that we have seen key indicators in China stabilize since we began accepting new sales leader applications in May after a three-month voluntary cessation. Moreover, we recently received a new direct selling license for Wenzhou, China, expanding our direct selling footprint in this important market.

"We will continue to innovate in the dynamic anti-aging product category to drive growth in consumer demand as well as interest in Nu Skin's business opportunity. We are encouraged with our product development pipeline with important new offerings in both skin care and nutrition next year, which we believe will lead to renewed global growth in 2015 and drive enhanced value for our shareholders."

For earnings history and earnings-related data on Nu Skin Enterprises Inc. (NUS) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Universal Insurance (UVE) Tops Q1 EPS by 10c
• Robert Half International (RHI) Reports In-Line Q1 EPS